Clinically relevant prognostic markers for prostate cancer: The search goes on

Annals of Internal Medicine

Volumn 150, Issue 9, 2009, Pages 647-649

  Gelmann, Edward P ^a   Henshall, Susan M ^b  

^a Milstein Hospital   (United States)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER SCREENING; EDITORIAL; GENE EXPRESSION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; HUMAN; MALE; MORTALITY; NOTE; PROGNOSIS; PROSTATE TUMOR;

TUMOR MARKER;

HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 65649138431     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-9-200905050-00014     Document Type: Editorial

References (15)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. [PMID: 18287387]
2. Scardino PT. Localized prostate cancer is rarely a fatal disease [Editorial]. Nat Clin Pract Urol. 2008;5:1. [PMID: 18185510]
3. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144-54. [PMID: 18695132]
4. Andriole GL, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9. [PMID: 19297565]
5. Schröder FH, HugossonJ, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8. [PMID: 19297566]
6. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, et al; EORTC 22911. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007;25:4178-86. [PMID: 17878474]
7. Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol. 2007;25:110-4. [PMID: 17349524]
8. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956-62. [PMID: 19167731]
9. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol. 1994;18:796-803. [PMID: 8037294]
10. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol. 1997;21:566-76. [PMID: 9158682]
11. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, et al. Independent origin ofmultiple foci ofprostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer. 1998;83:1995-2002. [PMID: 9806659]
12. Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Ann Intern Med. 2009;150:595-603.
13. Krupski T, Petroni GR, Frierson HF Jr, Theodorescu JU. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology. 2000;55:743-9. [PMID: 10792093]
14. Concato J. What will the emperor say?: screening for prostate cancer as of 2008. Cancer J. 2009;15:7-12. [PMID: 19197166]
15. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-83. [PMID: 19276453]